An Open-label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors

Principal Investigator

Shivaani Kummar

Study Purpose

The purpose of this study is to find out if the investigational drug called ORIC-101 is safe in people with a variety of different cancers and what effects it has on cancer.

Medical Condition(s)

advanced cancer

Eligibility Criteria

Male and Female participants of 18 years of age and older.
Diagnosed with advanced or metastatic cancer.

Age Range

18 - 99

Healthy Volunteers Needed


Duration of Participation

How long you participate in this study depends on side effects you may have to the study drug. It also depends on how your cancer might respond to the study drug.
If your cancer improves or stays the same and you do not have serious side effects from the study drug, you may remain in the study as long as your study doctor feels you may benefit. However, you are free to stop taking part in this study at any time and for any reason.

Minors Included



Knight Clinical Trials Information Line


ORIC Pharmaceuticals

Recruitment End


Compensation Provided


Go Back